Treating Cancer with Bispecific Antibodies: Current Status and Future Directions

SELF STUDY / ENDURING - ESTIMATED TIME TO COMPLETE ACTIVITY: 60 Minutes

Overview

The development of bispecific antibodies opened a new avenue of therapeutic options in oncology. During this webcast, participants will review the current role of bispecific antibodies in treating patients diagnosed with cancer, as well as management strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.

Target Audience

This CME initiative was designed for oncologists, surgeons, radiation oncologists, NPs, PAs, pharmacists, nurses, and other healthcare professionals involved in the treatment of patients with cancer.

Learning Objectives

1. Discuss the current indications of bispecific antibodies in oncology
2. Identify new and emerging clinical data regarding the role of bispecific antibodies in cancer treatment
3. Review the pharmacology and clinical challenges related to the use of bispecific antibodies
4. Describe management strategies for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in the context of bispecific antibodies therapy
 

Course summary
Available credit: 
  • 0.75 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 0.75 credit.
Course opens: 
09/15/2023
Course expires: 
09/15/2024
Cost:
$0.00
Rating: 
0

Faculty

Stephen Clark, PharmD, BCOP

Dr. Stephen Clark is a Clinical Pharmacy Specialist in malignant hematology at the UNC Medical Center. He completed a PGY2 Hematology Oncology Pharmacy Residency at Georgia Regents Medical Center and the University of Georgia in 2013. He completed his PGY1 Pharmacy Practice Residency at Sarasota Memorial Hospital in Sarasota, FL and his PharmD at the University of North Carolina Eshelman School of Pharmacy. He serves as Research Lead for UNC’s Oncology Pharmacy Residency Program. Dr. Clark enjoys assisting with refugee resettlement, playing board games, reading with his wife and two sons, playing basketball, and cooking.

 

Disclosures:

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, Horizon CME (HCME) ensures that continuing education activities are balanced, independent, objective, and scientifically rigorous. 

All persons in a position to influence the content of an accredited continuing education activity provided by Horizon CME are required to disclose to HCME any relevant financial relationships with ineligible companies within the past 24 months. All reported relevant financial relationships have been mitigated by Horizon CME.

Stephen Clark, PharmD, BCOP  discloses no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 24 months.

Available Credit

  • 0.75 AMA PRA Category 1 Credit™
    Horizon CME designates this Enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 0.75 ANCC
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME. The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. This course is approved by the Nurse Practitioner Healthcare Foundation, California Board of Registered Nursing, CEP# 16441. Upon completion, NPs and RNs will be awarded up to 0.75 credit.

Price

Cost:
$0.00
Please login or register to take this course.

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Read the CME/CE information and faculty disclosures.
  2. Participate in the online activity.
  3. Complete the post-test and score a minimum of 70%
  4. Submit the evaluation form

DISCLAIMER:

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Required Hardware/software

Access to the internet is required.

Supported Browsers:

Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 6.0+ for Mac OSX 10.7 and above

 

Supported Phones & Tablets:

 Android 4.0.3 and above

iPhone/iPad with iOS 6.1 or above